Physician profile
Alison Walgama
NPI 1356636146
$6,669.16
in general payments reported to CMS, 2019-2025
44 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $646 · 2021: $904 · 2022: $1,199 · 2023: $1,175 · 2024: $900 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,677.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $915.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $910.91 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $536.67 | 2020-2025 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $469.95 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $361.75 | 2019-2025 | Belsomra, Steglatro, Steglujan |
| Novartis Pharmaceuticals Corporation | $348.86 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.54 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $294.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $277.39 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $268.15 | 2019-2025 | Airsupra |
| Teva Pharmaceuticals USA, INC. | $239.41 | 2021-2024 | Ajovy, Austedo, Austedo Xr |
| Pfizer INC. | $228.35 | 2019-2024 | |
| Glaxosmithkline, LLC. | $208.55 | 2019-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $152.16 | 2023-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $106.97 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Walgama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.